A drug which boosts the body s immune system has been found as an exciting step forward in the battle against skin cancer.Four-in-10 patients who had a deadly skin cancer were still alive after three years after being given the drug.What s even more promising is that 15 per cent of those that were given the drug showed no signs of cancer at all.While the human body is incredibly capable of fighting infections, it has a lot of safeguards built in to stop it attacking human tissues.President-elect of the American Society of Clinical Oncology Dr Daniel Hayes explained the importance of this drug: This has been a bad disease, it s hard to treat, it s a sneaky disease and the mortality rates have been enormous so to see 40% of patients alive at three years is really a step forward.Thanks to some very early and clear successes with the drug the findings are already being put into action with the NHS approving pembrolizumab for patients with melanoma.
MoreFrench multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris, France, March 8, 2016.REUTERS/Philippe Wojazer/File PhotoBy Ben Hirschler and Greg Roumeliotis Reuters - French drugmaker Sanofi named eight candidates to replace the entire board of Medivation Inc on Wednesday, stepping up pressure on the U.S. cancer drug company which has rejected its $9.3 billion 6.3 billion pounds takeover approach."HAND-PICKED NOMINEES"Sanofi's nominees for Medivation's board are Michael Campbell, Barbara Deptula, Wendy Lane, Ronald Rolfe, Steven Shulman, Charles Slacik, James Tyree and David Wilson -- a roster of independent candidates with experience in the drug industry, finance and the law.Campbell led Arch Chemicals, before it was sold to Lonza in 2011 for $1.2 billion, while Deptula headed corporate development at Shire .If that is accurate, we cannot see how you have not done so with us," he wrote.Sanofi wants Medivation - which sells a successful prostate cancer drug called Xtandi and has others in development - to expand in the lucrative oncology sector, as it seeks new businesses to compensate for flagging diabetes revenues.
Stock Photo ID: 37245157 Close up of pink badge on woman chest to support breast cancer cause, PS: you can change the ribbon color to red to support AIDS cause as both using same symbol OtnaYdur View PortfolioScientific researchers have suggested that most forms of breast cancer may be prevented by taking a type of drug already on the market.Women from mainland China contributed more than 12 per cent of new breast cancer cases worldwide, according to a research paper published by the medical journal Lancet Oncology in 2014 .Rankl is a protein that passes chemical signals to the molecule to regulate its activities.The drug Denosumab is already on the market with Food and Drug Administration approval in the US after clinical trials proved its safety.We proposed five years ago that a rankl blockade could be used to prevent breast cancer, but it was ignored because I was told one needs data in a high risk cancer population, said Penninger.Our dream is that in the future Angelina Jolie would not need to amputate her breast, and of course millions of other women, he said, referring to the Hollywood actress who had a double mastectomy three years ago because of the high genetic risk of her getting breast cancer.
Robert "Bob" Greifeld, chief executive officer of Nasdaq OMX Group.Photo: Bloomberg, Billy H.C. KwokUnfazed by China s lingering economic slowdown, the head of the Nasdaq sees a new wave of technology companies leading the charge of mainland firms going public this year in the world s second-largest exchange by market capitalisation.The vast majority of those interested in listing in the US ... are from TMT the technology-media-telecommunications sector , where there is a range of opportunities, Greifeld said.We have a decent shot of having at least 10 initial public offerings IPOs come to the US from China this year.Data from the New York-based Nasdaq showed that the average number of Chinese companies listing on the exchange has reached 11 annually over the past four years.Founded in Beijing, the company is developing what it has described as the next generation of cancer treatment, which includes novel molecularly targeted and immuno-oncology therapeutics.
The deal officially closed June 1.In data released Sunday at the American Society of Clinical Oncology conference, Stemcentrx showed that its drug could extend the lives of certain patients with small cell lung cancer.Rova-T works by latching onto the protein, delivering the deadly toxin to the cell, and cutting off the tumor growth at its source.The Phase 1 study released Sunday, which had the goal of showing that Rova-T is effective and safe to use, looked at 74 people with small cell lung cancer whose disease had gotten worse even with at least one other treatment option.Although these results are preliminary, rovalpituzumab tesirine seems to be the first targeted therapy to show efficacy in small cell lung cancer, and we may have identified DLL3 as the first predictive biomarker in this disease, Dr. Charles Rudin, an oncologist at Memorial Sloan Kettering who led the study, said in a release.What's nextSan Francisco-based Stemcentrx, which has been been working on its drugs since 2008 but only launched publicly in September 2015.Since the acquisition by AbbVie, CEO Brian Slingerland told Business Insider, not much has changed in the day-to-day operations."NOW WATCH: Doctors just replaced cancerous bones in a man s spine with 3D-printed vertebraeLoading video...
Photo: Flickr/Christina Tu, Sue & Bill Gross Stem Cell Research CenterUntil now, the second-largest acquisition in the history of venture capital was largely based on clinical-trial data that hadn't been released.In data released Sunday at the American Society of Clinical Oncology conference, Stemcentrx showed that its drug could extend the lives of certain patients with small-cell lung cancer.The Phase 1 study released Sunday, which had the goal of showing that Rova-T is effective and safe to use, looked at 74 people with small-cell lung cancer whose disease had gotten worse even with at least one other treatment option.Although these results are preliminary, rovalpituzumab tesirine seems to be the first targeted therapy to show efficacy in small cell lung cancer, and we may have identified DLL3 as the first predictive biomarker in this disease, Dr. Charles Rudin, an oncologist at Memorial Sloan Kettering who led the study, said in a release.What's nextSan Francisco-based Stemcentrx, which has been working on its drugs since 2008 but only launched publicly in September 2015.Since the acquisition by AbbVie, according to CEO Brian Slingerland, not much has changed in the day-to-day operations.
U.S. Vice President Joe Biden speaks at the American Society of Clinical Oncology Annual Meeting in Chicago.U.S. Vice President Joe Biden said on Monday the moonshot initiative he leads aimed at finding cures for cancer was the only bipartisan thing left in America and called for more collaboration among researchers, doctors and government agencies to advance the cause.Biden was speaking at the American Society of Clinical Oncology meeting in Chicago in conjunction with the launch of a new system to facilitate sharing of genomic and clinical data among cancer researchers to help promote advances in personalized treatment for the many forms of the disease.Funding for GDC will come from $70 million allocated to NCI for cancer genomics projects under the precision medicine initiative, which involves using advanced genetic information to match individual patients with treatments most likely to help their particular type of cancer.More and more medicines are being developed that address specific genetic mutations associated with a variety of cancers and tumor types.Biden said he hoped efforts like the moonshot and GDC will help researchers spend more productive time in the lab and less writing grant proposals.
New data released Saturday at the American Society of Clinical Oncology annual conference in Chicago took a look at how liquid biopsies could influence how we treat cancer.These tests rely on something called "circulating tumor DNA", or the bits of DNA that are released from dying tumor cells into the bloodstream.Knowing what abnormalities a specific tumor possesses could help link cancer patients to treatments that specifically target those mutations as a more effective way approach cancer treatment.But the study did show some limitations: liquid biopsies were only able to pick up circulating tumor DNA mutations in 83% of the samples."Indeed, Foundation Medicine, which has both solid tumor sequencing tests and now a liquid biopsy test offers a dual-approach.Foundation's president and chief operating officer Steve Kafka told Business Insider that tissue biopsies will still be the gold standard, but there is one key area where liquid biopsy could make a major impact."What's exciting about liquid biopsy is — and we think this is going to be an important part of the picture — we believe this will allow physicians to now offer genomic insight to a broader swath of patients for whom tissue is not available," Kafka said.For some patients, there's not enough tissue to get, or they might be too sick to go into a surgical procedure to get the tissue removed."In the latest version of the test is that for the major cancer types, like lung and liver cancers, and ovarian cancer, we're exceeding 90% detection rates in all of those cancer types," he told Business Insider.Eltoukhy thinks it's a matter of time before liquid biopsies are more commonly adopted, comparing the situation to the adoption of wireless phones, where at first it seemed like landlines would still be critical in certain situations, but now cord-cutting is perfectly acceptable.
The internet is a great place for crowdsourcing data, and according to a new research by Microsoft, online search terms could lead to identifying cancer patients before they re diagnosed.The research, published this week on The Journal of Oncology, claims that by analyzing search engine queries from Bing, specifically, the team could spot early detections of those potentially suffering pancreatic cancer.While the Microsoft team did say they found patterns of search queries, it did not release exactly what symptoms could be considered warning signs of the disease.It did say, however, that it was able to identity potential patients with about 15 percent of the cases.The team hopes that with further research, it may be able to better identify the patients to help them seek treatment as soon as possible.We are excited about applying this analytical pipeline to other devastating and hard-to-detect diseases, one of the team s researchers said.
Searched-for symptoms form tell-tale signs of illnessSearch engine results are a useful predictor for cancer and can even beat doctors to the mark, according to new research from Microsoft.In a paper published in the Journal of Oncology Practice, the team detailed how, by analyzing data from Bing users who asked for details about pancreatic cancer, they could get an accurate diagnosis between 6 and 32 per cent of the time, with an error rate of 0.00001 per cent."We have shown that we can predict evidence of the future issuance of experiential queries about pancreatic cancer well in advance of their appearance in individuals' query streams at low error rate," the paper states."The success of these methods has implications for online methods that would provide passive screening of searchers with a view to providing early warning about potential signs of pancreatic adenocarcinoma and other devastating diseases."All the search data was, of course, anonymized, so the team surmised a diagnosis from user searches for specific treatments, such as pancreaticoduodenectomy, or for cancer medications such as gemcitabine and 5-fluorouracil.They then searched through the past history of searches looking for times when people binged common symptoms of pancreatic cancer, such as sudden weight loss, dark urine, or blood clots.
Microsoft claims to have developed the powerful pre-cognitive gift of being able to warn of cancer risk in people before they've even been diagnosed thanks to data taken from its Bing search engine.Why advertise with usThis level of search intel could lead to providing early warning flags to serious illness that can be life-saving, particularly for diseases like cancer, buying victims valuable treatment time, it said in a blog post.Eric Horvitz and Ryen White, part of the Microsoft research team, published their study in the Journal of Oncology Practice with findings that internet-diagnosis could one day hopefully prove more effective as X-ray or MRI in detecting illness before it's too late.With most of us these days jumping onto the internet rather than heading down to the doctors to find answers and help shed some light on certain health problems, there is a trove of data and search behaviour analytics available.The data could play a part in the future of medicine, acting like "a different kind of sensor or monitoring system" or perhaps a system linked into your GP that can give them an alert to when you perform a string of health searches related to a particular time-of-the-essence illness.We also can't ignore the privacy concern around your search data but won't have to worry for now as it's only a "proof of concept".
Unfortunately, far too often those headlines take a great piece of science and sell it as if it will single-handedly solve the cancer problem.I want to pause to acknowledge some of our less publicly celebrated science: the scientists who work behind the headlines to make the everyday doing of research quicker and easier.I just couldn t get the technique to work and I had no idea why.It had lots of repeat sequences and my experimental difficulties were caused by it sticking to itself like a misbehaving piece of cling film.Imagine if instead a professional chef did all that fiddly prep work for you and delivered everything to your house in neat little packets so you just need to assemble it in your dish and pop it in the oven.I certainly didn t appreciate the efforts of those scientists enough when I worked in the lab so I m putting right that failure now.
A revolutionary device called the Mobetron is being trialled in a UK hospital to help fight cancer.The Mobetron is the first portable system able to administer the treatment in this way - known as intraoperative radiotherapy IORT - and will start being used in operating theatres at Southampton General Hospital this month.It is used pre-surgery to shrink tumours, and post-surgery to reduce the chances of the cancer coming back.Press Association reported: This enables surgeons and oncology specialists to deliver much higher doses of the anti-cancer treatment to areas at a high risk of recurrence without causing damage to surrounding healthy tissue and organs seen with conventional external beam radiotherapy.The system, tested by experts at the National Physical Laboratory in London before being transported to Southampton, will be used initially to treat patients with pancreatic, neuroendocrine, colorectal and bladder tumours.Surgeon Neil Pearce said: This is a landmark moment for the treatment of advanced cancer in Southampton and across the UK.
trophygeekDespite brimming data showing that drinking coffee can be good for your health, there has been a lingering black stain on the popular drink s reputation—the 1991 assessment by the World Health Organization that classified coffee as a possible carcinogen.In a Wednesday announcement and an accompanying article in the journal The Lancet Oncology, the WHO reversed that 1991 classification, striking coffee from the Group 2b list of foods and beverages that are possibly carcinogenic to humans.That initial classification was based on limited evidence of an association with cancer of the urinary bladder from case-control studies, and inadequate evidence of carcinogenicity in experimental animals.For more than 20 other types of cancers, the effect of coffee drinking was inconclusive, the experts found.Similarly, the experts reviewed data on maté, a strong caffeinated drink particularly popular in South America.In the US, standard coffee serving temperatures range from 70 to 85 degrees Celsius 158 to 185 degrees Fahrenheit .
What won Alexis Borisy over was the idea of software bugs.Borisy, now a partner at Third Rock Ventures, along with four scientists affiliated with MIT and Harvard's Broad Institute who were leaders in cancer genomics got started back in 2008 working on what would soon become Foundation Medicine No.62 on the BI 100: The Creators , a company that sequences the DNA in cancer cells to get a better idea of what's going on.That's where the software bugs come into play: The way Borisy sees it, cancer is a "disease of the human programming code.""We need to figure out how to get this done in high quality way so it can be used day in day out in the practice of oncology," he remembers the conversations going.Building the teamThe company got its start on the fourth floor of Third Rock, which was Foundation's founding member.Borisy served as the company's first CEO, eventually becoming a partner at Third Rock in 2010, where he's gotten the chance to build up other biotechnology companies.It's been a great partnership," Borisy said of Pellini and Kafka's roles.Along the way, Foundation picked up backing from Google Ventures and Bill Gates before going public in 2013.Swiss pharma giant Rochealso holds a majority stake in the company.Finding the bugs and creating valueFoundation Medicinetries to help patients and doctors facing seriously hard-to-treat cancers by looking at the genetic makeup of that cancer for example, the genetic mutations in a breast cancer patient could actually look more like a patient with colon cancer and thus those types of treatments could work better .To do that, Foundation collects samples from cancer patients."Read more stories about the 100 business visionaries who are creating value for the world.NOW WATCH: Watch science writer Carl Zimmer explain CRISPR in 90 secondsLoading video...
Around 1,300 people could be eligible for the immunotherapy drugs every year, and people with advanced skin cancer currently live less than two years on average.Nice moved quickly on the drug approval after the results of a phase II study into the drugs showed startling results in April.Of 95 patients given the combined treatment, more than 60% were still alive after two years and, of those, a fifth 22% had no detectable tumours remaining.Each blocks a separate receptor switch on immune system T-cells that weakens the immune response and can be activated by molecules released by tumours.Checkpoint inhibitors can have side effects, including causing diarrhoea and liver damage.Research presented at the American Society of Clinical Oncology Asco conference last week showed that of 38 patients given the drugs, 47% responded, with more than 83% still alive after a year.
Go ahead, have another cup of coffee, the World Health Organization says it s OK.The International Agency for Research on Cancer IARC , a group of 23 scientists who make up a WHO Working Group, released the results of their examination of scientific studies about the potential cancer risks of coffee, maté, and very hot drinks.After reviewing more than 1,000 previous studies, the IARC released a summary of its findings.The full analysis was published in The Lancet Oncology.However, the experts did find that drinking very hot beverages 140 degrees or higher probably causes cancer of the oesophagus in humans.So not only is coffee essentially cleared for causing cancer in other organs, it looks like it can help prevent liver and uterine cancer.
Illumina s success has enabled a diverse set of genomics applications: prenatal testing, agriculture, drug development, clinical trial recruitment, oncology, nutrition and fitness, and many more yet to be invented.DNA sequencing reads, the raw output of a sequencing machine, need to be processed to properly identify variants that are the representative variable differences among genomes and the focus of any further application or study.The question facing many life sciences enterprises is whether the Genomics Tech Stack is at the good enough stage where modular components can be swapped in and out to build scalable workflows, or can enterprises only trust fully integrated, vertically assembled systems?Clay Christensen proposes a theory that integrated systems are always better until they aren t: When products become good enough for the market, integrated systems actually overserve most customers and modular products become cheaper to produce and distribute because each part of the supply chain becomes standardized and optimized.Nonetheless, for a business, it is crucial to evaluate the ROI of vertically integrated solutions versus modular external substitutes.Reproducibility and automation are especially difficult for homespun systems whose components are open source, unsupported and/or non-existent.
Berkeley who was selected for his discoveries related to ubiquitylation which could enable scientists to come up with next-generation therapies in oncology, immunology, and inflammation.What that detection did was to show that it was possible; that these planets really did pass in front of their stars.Once people saw how much information we were getting, it was a big shot in the arm of NASA to pick the Kepler mission and fly it.Dr. David CharbonneauWhile the concept of the Kepler Space Telescope had been around for decades, Charbonneau s work confirmed that detecting and analyzing exoplanet transits would be worthwhile and lead to fruitful results.We thought we would have to search vast distances to find an Earth-like planet.And that young scientists, despite being young, can often make the most important contributions in science.
We can take all the DNA in our body and turn it into letters on a hard drive, says Jimmy Lin, the Chief Scientific Officer for Oncology at Natera, a genetic testing company.On Wednesday at SparkLabs Demo Day in Seoul, Dr. Lin and Laurent De Vitton, the co-founder of  Apricot Forest 杏树林 , a healthcare startup based in Beijing, highlighted opportunities and challenges for startups eyeing the healthcare industry, which is in many ways one of the final frontiers for consumer technology.Smartphone applications in the healthcare industry, however, are much more niche, like smartphone microscopy, which can help doctors without access to expensive medical devices detect diseases like skin cancer or malaria.Individuals in the West, but also Asia, understand less and less why their shopping experience has  been so revolutionized by the smartphone, why their entertainment life has been so deeply transformed, but  why their health is barely impacted as far as their personal experience goes, says Mr. De Vitton.Improving user experiences in the healthcare industry is a huge opportunity for startups.In China, for example, overextended doctors juggle excruciating caseloads, sometimes seeing fifty patients a day, averaging to about less than five minutes per patient, says Mr. De Vitton.Lowering the rate of misdiagnosis and improving patient service can come from simple solutions, like Apricot Forest s suite of apps, which digitizes patient case files and enables doctors to crowdsource solutions and diagnoses from other doctors.Big data also opens a lot of doors for healthcare startups.